drugset

drugset / Trial / NCT07022119

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT07022119 ↗

Phase 1 Completed 32 enrolled Vertex Pharmaceuticals Incorporated

RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of VX-407 in healthy participants.

Timeline

Start: 2025-06-12
Primary completion: 2026-02-24
Completion: 2026-02-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VX-407	Unknown	—	Oral

Indications